In most patients with cancer we cannot control the development and growth of metastases. But in a few, most notably those with cancer of the breast, remarkable remissions of the disease may take place when the endocrine environment is altered by administration of hormones or ablation of endocrine glands. When treated in this way fungating lesions of the breast may shrink and heal, lytic lesions of bone recalcify and remodel and leukocrythroblastic blood pictures return to normal. This state of affairs lasts on average for 18 months to 2 years and then the disease progresses again.
Many methods are available by which remission may be achieved. They include a wide range of hormones including androgens, oestrogens, progestogens and corticosteroids and removal or ablation of the ovaries, adrenals and pituitary. In addition radiotherapy and a wide range of cytotoxic drugs may have some part to play. Unfortunately confusion still exists about the indications for and the relative value of the various forms of treatment. In one review (Forrest 1967) most patients were found to have received at least 3 types of treatment and many had received 5 or even more. But the choice of treatments and the order in which they were given varied greatly and seemed to follow no rational plan. This study was carried out in the hope that the results would help towards a rational programme for the management of women with advanced cancer of the breast.
Timing ofMajor Endocrine Ablation
One of the most controversial problems has been the timing of the major ablative operations of adrenalectomy and hypophysectomy. Some surgeons have suggested that these operations should be used as a last resort and have considered it unreasonable to start treatment with a major operation when the simple administration of hormone tablets might have the same effect. Others believed that many patients might deteriorate rapidly while being treated with hormones and die or become unfit for surgery before they could receive the advantage of adrenalectomy or hypophysectomy. The main object of the first part of this study was to determine whether pituitary ablation should be carried out as soon as it became apparent that the disease was advanced (early ablation) or kept as a last resort until more simple methods had failed (late ablation).
Method: All patients in whom there was considered to be no prospect of cure were considered for the trial. They included those with large fixed local tumours (T3 and T4), those with fixed axillary lymph nodes or involved supra clavicular nodes (N2 and N3), those with locally recurrent disease after mastectomy and those with distant metastases (Ml). Patients who had received previous endocrine therapy and those unfit for pituitary ablation were excluded. Patients with solitary painful metastases and those with fungating local lesions were treated initially by radiotherapy and admitted to the trial at a later stage.
When accepted for the trial the patients were allocated randomly into 2 groups. Those in the first group were treated at once by ablation of the pituitary and those in the second received a course of simple endocrine therapy and eventually a pituitary ablation, when simple methods had failed. The trial was stratified to take into account the site or sites of the disease and the menopausal status of the patients. In this way the patients were paired into 9 sub-groups according to whether they had osseous metastases only, local disease only or disease at other sites or combinations of sites and according to whether they were premenopausal, less than five years postmenopausal or more than five years postmenopausal.
Ablation of the pituitary was performed by insertion of rods of radioactive yttrium-90 into the gland under X-ray control. The course of simple endocrine therapy varied according to whether patients were premenopausal or post-menopausal. In premenopausal women the initial treatment was bilateral oophorectomy and when patients failed to respond or when a response was followed by progression of the disease a course of fluoxymesterone (5 mg three times daily) was given. When this failed ablation of the pituitary was carried out. In postmenopausal women the initial treatment was with stilbeestrol S mg three times daily, or ethinylcestradiol 0.1 mg, if stilbeestrol proved too irritant, and this was followed by fluoxymesterone (5 mg three times daily) and eventually by ablation of the pituitary.
Response was assessed at intervals of three months after the start of treatment. Only objective criteria were considered and clear objective evidence of regression of all lesions without the appearance of any new ones was needed before a patient was considered to have responded.
Of the 113 patients admitted to the trial 108 were paired as described previously. In the results which follow only these 54 pairs are considered.
Results: The choice of treatment did not apparently influence the incidence of response. Of the 54 patients treated by early ablation of the pituitary, 13 (22%) responded to treatment. Of the 54 treated by the late ablation regime 15 (27%) responded at some stage. This difference was quite insignificant.
Of the 54 pairs of patients 47 pairs consisted of postmenopausal women. Of the 47 treated initially by pituitary ablation, 9 (19%) responded and of the 47 treated initially with stilbmestrol, 13 (27 %) responded to the oestrogen. This difference although marked was not statistically significant.
Of the 54 patients treated by the late ablation regime, 16 (30%) went downhill rapidly and died before ablation could be carried out. In spite of this, the survival curve for the group treated by early ablation was virtually identical with that for the group treated by the late ablation regime (Fig 1) .
Conclusion: There is no advantage to be gained by early ablation of the pituitary in patients with 
Value ofthe Discriminant Function
None of the forms of treatment considered has resulted in an incidence of response of greater than 27 %. This implies that the great majority of patients were subjected, quite unnecessarily, in the terminal stages of their illness to operations and other unpleasant forms of treatment which availed them nothing. Clearly a means of distinguishing those who are likely to respond from those who are not is needed urgently. One of the most promising fields for research has derived from the work of Sir Hedley Atkins and his colleagues at Guy's Hospital and the Imperial Cancer Research Fund who found that response to endocrine ablation could be related to the relative amounts of certain steroids in the patient's urine (Bulbrook et al. 1960) . They found that when the urinary 11-deoxy-17 oxosteroids were relatively high and the 17-hydroxysteroids low the results of adrenalectomy or hypophysectomy were likely to be good. Conversely when the 17-hydroxysteroids were high and the 1 1-deoxy-17 oxosteroids low operations were likely to fail. Patients could be separated into responsive and nonresponsive groups most effectively by considering the relationship between the 17-hydroxysteroids and one constituent of the 1 1-deoxy-17 oxosteroid fraction, etiocholanolone, by means of the following formula or discriminant function: 80-80 (17-hydroxysteroids (mg/24 h) ) + etiocholanolone (,ug/24 h).
When the amounts of 17-hydroxysteroids and ietiocholanolone in a patient's urine were substituted in the formula and the result of the sum was a positive number, the patient was said to have a positive discriminant and her disease was likely to respond to adrenalectomy or hypophysectomy. If the result was a negative number, she had a negative discriminant and operations were likely to fail.
Unfortunately the measurement of Ttiocholanolone is difficult and time-consuming and is not carried out in most routine laboratories, so Fotherby et al. (1968) at Hammersmith, devised a simple method for measuring two I 1-deoxy-17 oxosteroids, itiocholanolone and androsterone, together and suggested that a discriminant with the following formula might be equally effective: The main object of this part of the study was to determine the extent to which the Guy's discriminant' would separate potentially responsive from nonresponsive patients and to find out whether the more simple Hammersmith discriminant2 was equally effective.
Method: Two 24-hour samples of urine were collected on the third and fourth days after admission to hospital from 113 patients with advanced cancer of the breast. All samples were collected before treatment was started. The Guy's discriminant was measured in each sample and the Hammersmith discriminant in each sample from 108 of the patients. The results were expressed as the mean of the two observations for each patient.
Of the 113 patients 64 were treated within a few days of the urine collection by ablation of the pituitary with yttrium-90, 41 with stilbeestrol and 8 by bilateral oophorectomy. Response to treatment was assessed as described previously.
Results: When the values for the Guy's discriminant for each patient were plotted against those for the Hammersmith discriminant there was an excellent and highly significant correlation between them (p=0.09 P<0.001). The values which gave the best possible separation into responsive and nonresponsive patients were 0 for the Guy's discriminant and 0.11 for the Hammersmith discriminant.
Of 55 patients with a negative Guy's discriminant, 10 (18%) responded to treatment and of 52 with a positive discriminant, 20 (38 %) responded. This difference was significant (x2=4.59 P<0.05). The separation into response and nonresponsive groups was even more effective with the Hammersmith discriminant. Of 52 patients with a negative Hammersmith discriminant, 6 (11 %) responded to treatment and of 61 with a positive discriminant, 24 (39 %) responded (X2 =9.07 P<0.005).
The survival of patients with positive discriminants of either type was significantly longer than that of those with negative discriminants (Fig 2) . At one year after the start of treatment approximately 70% of patients with a positive discriminant were alive and only 40% of those with a negative discriminant.
Conclusion: Response to endocrine treatment is related to the value of the discriminant function. The simple quick Hammersmith discriminant is at least as effective as the more complicated Guy's discriminant.
Discussion
The results of the first study indicate clearly that there is no advantage to be gained from early ablative surgery even though a third of the patients in the late ablation group died before the operation could be carried out. In these circumstances it seems advisable to start treatment invariably with simple methods and to reserve adrenalectomy or hypophysectomy until later.
The results of the discriminant study confirm the relationship between urinary steroid excretion and responsiveness to endocrine treatment and suggest that the essential estimations can be carried out simply, cheaply and quickly. The incidence of response in patients with a negative discriminant, however, remains too high for patients to be excluded from treatment for this reason alone. Used in combination with other factors such as the 'free interval' or menopausal status which also affect response, it seems likely that the method may be of greater value. The incidence of response in patients who have both a negative discriminant and a short free interval and those who are less than five years postmenopausal and have a negative discriminant seldom, if ever, respond and these patients might well be spared the unnecessary assault of major ablative surgery. 
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Prevention of Recurrent Cancer of the Large Bowel
Each year some 15 000 patients die of large bowel cancer in England and Wales. Many of these have had previous so-called curative surgery yet subsequently develop either recurrent or metastatic disease. The fact that both these phenomena are so common means that our present knowledge about their prevention is pitifully small. Three mechanisms may be responsible for apparent local recurrence following resection: an overlooked second tumour or the development of a metachronous second primary; incomplete resection; and implantation of cells at the anastomosis, at any raw surface including the abdominal wound, and the peritoneal cavity at the time of surgery.
Disseminated secondaries probably represent the growth of microscopic foci already present at the initial resection, although it is possible that they result, in some instances, from tumour cells dislodged into the lymphatic or portal circulation during operation. What means are available to deal with these various possibilities ?
A second primary: Heald & Lockhart-Mummery (1972) stress the high incidence of a second tumour picked up within two years of the primary resection and which probably represents synchronous cancer missed at the initial operation. Routine sigmoidoscopy, barium enema studies and the more widespread use of the colonoscope should reduce this eventuality. Early pick up of metachronous cancers may be achieved by careful follow up. Heald & Lockhart-Mummery advocate six-monthly sigmoidoscopy and two-yearly double-contrast barium enema studies.
Incomplete resection: This is particularly likely to occur in anterior resections of the rectum. Unless being performed as a palliative measure, this should not be employed unless a comfortable 2 inches (5 cm) of rectum can be taken distal to the lower extremity of the tumour. Rectal sacrifice and a colostomy is preferable to a recurrence.
Prevention of implantations at the time ofsurgery:
Cancer cells shed at the time of surgery can undoubtedly seed at the anastomosis, on raw wound surfaces and over the peritoneum (Gilbertsen 1960 , Ryall 1907 , 1908 , Vink 1954 . The edges of the laparotomy wound should be meticulously protected by packs before the
